Search for: "Bristol Myers Squibb"
Results 641 - 660
of 866
Sorted by Relevance
|
Sort by Date
4 Feb 2013, 2:07 pm
Bristol—Myers Squibb Co., No. 07-1098 (FLW), 2013 U.S. [read post]
19 Jun 2014, 8:11 am
TAP Pharmaceuticals (Bristol Myers Squibb Appeal), No. 85 MAP 2011, slip op. [read post]
12 Oct 2018, 10:19 am
Freshbev LLC, 322 F.Supp.3d 330 (E.D.N.Y. 2018)Campbell bought several bottles of Freshbev juices at Whole Foods, allegedly relying on misrepresentations (1) that the juices were unpasteurized; (2) that the juices were cold-pressed; (3) that the juices were fresh; and (4) that the Cranberry Apple juice had more cranberry juice than apple juice.Initially, the court declined to resolve at this stage whether Bristol–Myers Squibb Co. v. [read post]
22 Oct 2018, 1:43 am
Indeed, both Upjohn and before Bristol-Myers Squibb and Others v Paranova (joined Cases C-427/93, 429/93 and 436/93) had indicated that “the requirement of artificial partitioning of the markets does not imply that the importer must demonstrate (emphasis added) that, by putting an identical product on the market in varying forms of packaging in different Member States, the trade mark proprietor deliberately sought to partition the markets between Member… [read post]
24 Sep 2017, 2:22 pm
., Professor and IACUC Chair, Rutgers University Elizabeth Dodemaide, BVSc, MA, MANZCVS, Director Comparative Medicine Resources, Rutgers University Gregory Reinhard, DVM, Director, Animal Welfare, University of Pennsylvania Strategies to Enhance Animal Welfare Compliance Monitoring Presenters: Pharmaceutical: Lisa Stanislawczyk, Bristol-Myers Squibb, CRO: Mary Ann Jacobs, Envigo Academic: Greg Reinhard, MBA, DVM, University of Pennsylvania, The Role of the Statistician… [read post]
11 Nov 2009, 4:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch) Prandin (Repaglinide) - US: Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O) General Eduardo Pisani of Bristol-Myers Squibb is the new IFPMA Director General (IP Watch) Is the… [read post]
25 Aug 2015, 10:55 am
The cases of Bristol-Myers Squibb v Paranova and Boehringer II in particular held that where a parallel importer re-packages goods, the following conditions must be satisfied to prevent infringement: The repacking must be objectively necessary to avoid market partitioning; The condition of the product must not be effected; The manufacturer and the importer must be clearly identified; The reputation of the mark and its owner must not be damaged; and The importer must give… [read post]
17 Feb 2010, 4:55 pm
Several years later, two of Abbott's competitors (GSK and Bristol-Myers Squibb) introduced two new PIs which were meant to be used in conjunction with booster quantities of Norvir. [read post]
3 Apr 2010, 4:02 pm
Where an ad is literally false, the court has the power enjoin the use without reference to the impact of the ad on the buying public (McNeil-PCC v Bristol-Myers Squibb)(1991)). [read post]
2 Jun 2010, 3:15 am
” Bristol-Myers Squibb Co., 326 F.3d at 1241; see Molins PLC, 48 F.3d at 1182 (“We recognize that [the withheld references] were cited eventually to the PTO and that the examiner . . . passed the reexamination application to issue thereafter. [read post]
9 Sep 2009, 7:14 am
– Dispute between Wyeth and Dexel (The IP Factor) EpiPen (Epinephrine) – US: King Pharmaceuticals, Meridian Medical Technology file patent infringement suit against Teva following Para IV certification (Patent Docs) Seroxat (Paroxetine) – Israel: not even sublime, just ridiculous – Israel PTO decision in Unipharm v SmithKline Beecham (America-Israel Patent Law) Stelara (Ustekinumab, anti-IL-12 antibody) – Centocor seeks review of BPAI decision… [read post]
4 Dec 2007, 6:33 pm
Bristol-Myers Squibb was the first company to develop and patent a liquid pharmaceutical composition of megestrol acetate and had a patent that taught that stable suspensions of megestrol acetate can be created but that the type and concentration of the surfactant in solution is critical to creating a stable flocculated suspension. [read post]
15 Dec 2008, 9:51 pm
The '265 patent covers clopidogrel bisulfate, the active ingredient in Sanofi and Bristol-Myers Squibb's blockbuster heart medication Plavix. [read post]
15 Oct 2008, 8:38 am
AAJ obtained emails that list attendees of a meeting between Bradshaw and the Pharmaceutical Research and Manufacturers of America (PhRMA) revealing the FDA chief counsel met with legal representatives from Pfizer, Wyeth, Eli Lilly, Berlex, Organon, Abbott Laboratories, Takeda, Sanofi-Aventis, Serono, AstraZeneca, Cephalon, Millenium, Eisai, Amgen, Astellas, GlaxoSmithKline, Bristol Myers Squibb, Johnson & Johnson, Novartis, Merck, and 3M.Less than six months after… [read post]
3 Jun 2008, 3:05 am
The following table also provides some interesting comparisons of patent strategy.[6] Type of Technology Number of Utility Patents in the Sample Number of Patents Referencing Provisional Parent Assignee Mechanical 24 1 4% Ford 25 13 52% GM Drugs & Medical 7 4 57% Wyeth 8 7 88% Genentech 11 1 9% Boston Scientific Scimed 21 10 48% Medtronic Computers & Communications 15 12 80% InterDigital 23 7 30% Oracle 31 11 35% QUALCOMM 44… [read post]
24 Mar 2015, 11:54 am
Xarelto, has grabbed a 32 percent market share in the highly competitive anticoagulant market, significantly ahead of Boehringer’s Pradaxa and Bristol-Myers Squibb’s Eliquis, the other two new anticoagulants in the market. [read post]
8 Mar 2012, 3:34 am
., Bristol-Myers Squibb Co., GlaxoSmithKline PLC and others that have disclosed investigations for possible FCPA breaches. [read post]
30 Jun 2017, 4:14 am
At The Washington Legal Foundation’s Legal Pulse blog, Richard Samp discusses Bristol-Myers Squibb Co. v. [read post]
22 Jan 2019, 2:09 am
One case, Bristol-Myers Squibb Co. v. [read post]
22 Aug 2012, 7:51 am
Bristol-Myers Squibb Co., resulting in $515 million settlement arising from unlawful conduct including off-label promotion to induce government purchases of the antipsychotic drug Abilify; and United States ex rel. [read post]
